Ototoxicity: a clinical review.
D000284:Administration, Oral; D000287:Administration, Topical; D000336:Aerosols; D000617:Aminoglycosides / Q000009:adverse effects; D000900:Anti-Bacterial Agents / Q000009:adverse effects; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects; D000981:Antiprotozoal Agents / Q000009:adverse effects; D001299:Audiometry; D003638:Deafness / Q000139:chemically induced* / Q000517:prevention & control; D004357:Drug Synergism; D007758:Ear, Inner / Q000187:drug effects; D004976:Ethacrynic Acid / Q000009:adverse effects; D005665:Furosemide / Q000009:adverse effects; D006494:Heparin Antagonists / Q000009:adverse effects; D006801:Humans; D007676:Kidney Failure, Chronic / Q000150:complications; D012459:Salicylates / Q000009:adverse effects; D013792:Thalidomide / Q000009:adverse effects; D007507:Therapeutic Irrigation; D013997:Time Factors; D014012:Tinnitus / Q000139:chemically induced; D014717:Vertigo / Q000139:chemically induced
D000336:Aerosols; D000617:Aminoglycosides; D000900:Anti-Bacterial Agents; D000903:Antibiotics, Antineoplastic; D000981:Antiprotozoal Agents; D006494:Heparin Antagonists; D012459:Salicylates; D013792:Thalidomide; D005665:Furosemide; D004976:Ethacrynic Acid